Press release archive 2010-2016

Oncopeptides Receives the SwedenBIO Award 2017

May 17, 2017

For the 11th time, SwedenBIO Award was awarded on Wednesday night.

Read more

Oncopeptides AB issues 977,906 shares additionally in connection with offer to acquire shares and listing on Nasdaq Stockholm (the “Offering”)

March 27, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

ABG Sundal Collier AB exercises the over-allotment option regarding 977,906 shares in Oncopeptides AB (publ)

March 24, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected

March 22, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today

February 22, 2017

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

Notice to attend an extraordinary shareholders’ meeting in Oncopeptides AB (Publ)

January 4, 2017

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, are hereby given notice to attend an extraordinary shareholders’ meeting to be held at the company’s premises on Västra Trädgårdsgatan...

Read more

Oncopeptides Welcomes New Board Member – Luigi Costa

August 15, 2016

Oncopeptides AB, a clinical stage company developing an effective, peptidase targeted therapy for the treatment of multiple myeloma announces the appointment of Luigi Costa to its Board of Directors.

Read more

Oncopeptides Present Phase 2 Clinical Data at the European Hematology Association in Copenhagen, Denmark, June 2016

July 7, 2016

Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – announced that clinical results from a Phase 2 study of melflufen and dexamethasone in patients with r...

Read more

Oncopeptides prepare for pivotal Phase 3 clinical trials

April 30, 2016

Oncopeptides have had a number of interactions with the regulatory authorities over the last months, and as a result the company will make preparations to be ready to begin pivotal Phase 3 clinical tr...

Read more

Oncopeptides have a successful meeting with MHRA

March 31, 2016

Oncopeptides had a successful meeting with MHRA on March 23rd to discuss the design of the upcoming pivotal trial of melflufen in late-stage relapsed and refractory multiple myeloma patients.

Read more

Oncopeptides CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma

January 13, 2016

Oncopeptides and CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma.

Read more

Oncopeptides presents latest efficacy results of melflufen in combination with dexamethasone at ASH

December 11, 2015

Oncopeptides AB, a clinical stage company developing a peptidase potentiated therapy – melflufen – presented clinical results from an ongoing Phase 2 study in patients with relapsed and relapsed refra...

Read more

Results Presented at EHA Show Significant Clinical Benefit, as Measured by Overall Response Rate and Progression Free Survival, when Treated with Melflufen and Dexamethasone

June 12, 2015

Heavily Pretreated, Relapsed and Relapsed Refractory Multiple Myeloma Patients Showed Significant Clinical Benefit, as Measured by Overall Response Rate and Progression Free Survival, when Treated wit...

Read more

Oncopeptides to Present Promising Phase I/ II Clinical Data at the European Hematology Association in Vienna, Austria, June 11 – 14 2015

June 4, 2015

Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – today announced that the clinical results from an ongoing Phase I/II study of safety and efficacy of m...

Read more

Oncopeptides Receives EMA and FDA Orphan Drug Designation for Melflufen in the Treatment of Multiple Myeloma

March 23, 2015

Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have both ...

Read more

Oncopeptides Presents Encouraging Preliminary Phase I/ II Clinical Data with Melflufen and Dexamethasone for Patients with Relapsed and RelapsedRefractory Multiple Myeloma at the 56th ASH Annual Meeting and Exposition

December 5, 2014

Oncopeptides AB, a clinical stage company developing a novel alkylator – melflufen – today announced that initial clinical data from the dose escalation part of a Phase I/II dose escalation/expansion ...

Read more

Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients

August 20, 2013

Stockholm, Sweden August 20, 2013 – Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myel...

Read more

Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients

May 21, 2013

Oncopeptides today announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; m...

Read more

Oncopeptides AB appoints Jakob Lindberg as CEO

October 21, 2011

STOCKHOLM, SWEDEN - October 21, 2011. Oncopeptides AB, a Karolinska Development AB portfolio company, today announced the appointment of Jakob Lindberg as new CEO. Mr. Lindberg holds a Med. Lic. in Mo...

Read more

Oncopeptides AB. Presents the New Anticancer Agent J1 at The American Society of Hematology Annual Meeting in Orlando, Florida

December 1, 2010

STOCKHOLM, SWEDEN – 1 December 2010 – Oncopeptides AB today announced that preclinical results for J1 will be presented this week-end at the ASH Annual Meeting in Orlando, Florida, USA. The abstract 1...

Read more

Oncopeptides Announce New Chairman of the Board

April 19, 2010

Read more